Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program
26 February 2026
No Comments
U.S. Investigational New Drug (IND) applications for radiotheranostic pair PentixaFor and PentixaTher became active